Search | Clinical Trials Finder

Conditions: Gastrointestinal Stromal Tumors
Interventions: AMN107, STI571; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Chronic Myeloid Leukemia
Interventions: Nilotinib; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Chronic Myelogenous Leukemia
Interventions: Nilotinib followed by treatment-free; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 10
States / cities: Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Nilotinib, Placebo to nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more

Conditions: Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Interventions: nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 10
States / cities: Loma Linda, California • Palo Alto, California • Orlando, Florida + 7 more

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Interventions: Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab; Drug · Other · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 291
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more

Conditions: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 24
States / cities: Duarte, California • Stanford, California • Aurora, Colorado + 20 more

Conditions: Chronic Myelogenous Leukemia
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 19
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Gastrointestinal Stromal Tumor (GIST)
Interventions: Nilotinib (AMN107), imatinib (STI571); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 28
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Duarte, California + 22 more

Conditions: CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Interventions: nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Las Vegas, Nevada • Amarillo, Texas • Dallas, Texas

Conditions: Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Leukemia
Interventions: Dasatinib, Imatinib Mesylate, Nilotinib; Drug
Lead sponsor: Emory University; Other
Eligibility: 17 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chordoma
Interventions: Nilotinib, Radiation therapy; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Albany, New York • Houston, Texas

Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions: nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Healthy
Interventions: Nilotinib Hydrochloride, calcium carbonate; Drug · Dietary Supplement
Lead sponsor: Jan Beumer; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Myeloid Leukemia
Interventions: nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more

Conditions: Leukemia, Myelogenous, Chronic
Interventions: Nilotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: Nilotinib, DTIC; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 14
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 11 more

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions: Dasatinib, Imatinib Mesylate, Nilotinib, Ruxolitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: MEK-162, Nilotinib, Questionnaires; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelogenous Leukemia, Chronic
Interventions: nilotinib, imatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • Vallejo, California + 27 more

Conditions: Neurofibromatosis, NF1, Neurofibromas
Interventions: Tasigna; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral
Interventions: Nilotinib; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Stanford, California • Denver, Colorado • Buffalo, New York + 1 more

Search by objective public record fields.

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

A Study of Nilotinib Versus Imatinib in GIST Patients

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Nilotinib With Radiation for High Risk Chordoma

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease